6534 — CH Biotech R&D Co Balance Sheet
0.000.00%
- TWD8.23bn
- TWD8.23bn
- TWD1.51bn
- 72
- 43
- 33
- 47
Annual balance sheet for CH Biotech R&D Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 282 | 324 | 321 | 530 | 943 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 31.6 | 36.5 | 161 | 33.8 | 106 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 413 | 442 | 655 | 804 | 1,235 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,329 | 2,390 | 2,358 | 2,365 | 2,361 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2,791 | 2,879 | 3,029 | 3,195 | 3,649 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 379 | 450 | 529 | 468 | 882 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,313 | 1,399 | 1,306 | 1,108 | 1,129 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1,478 | 1,480 | 1,723 | 2,088 | 2,520 |
Total Liabilities & Shareholders' Equity | 2,791 | 2,879 | 3,029 | 3,195 | 3,649 |
Total Common Shares Outstanding |